{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:19:08Z","timestamp":1790738348536,"version":"4.1.0"},"reference-count":44,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Atrium Health Foundation","award":["5713"],"award-info":[{"award-number":["5713"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Many cancer patients still lack effective treatments, and pre-existing or acquired resistance limits the clinical benefit of even the most advanced medicines. Recently, much attention has been given to the role of metabolism in cancer, expanding from the Warburg effect to highlight unique patterns that, in turn, may improve diagnostic and therapeutic approaches. Our recent metabolomics study revealed that ribitol can alter glycolysis in breast cancer cells. In the current study, we investigate the combinatorial effects of ribitol with several other anticancer drugs (chrysin, lonidamine, GSK2837808A, CB-839, JQ1, and shikonin) in various breast cancer cells (MDA-MB-231, MCF-7, and T-47D). The combination of ribitol with JQ1 synergistically inhibited the proliferation and migration of breast cancer cells cell-type dependently, only observed in the triple-negative MDA-MB-231 breast cancer cells. This synergy is associated with the differential effects of the 2 compounds on expression of the genes involved in cell survival and death, specifically downregulation in c-Myc and other anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1), but upregulation in p53 and cytochrome C levels. Glycolysis is differentially altered, with significant downregulation of glucose-6-phosphate and lactate by ribitol and JQ1, respectively. The overall effect of the combined treatment on metabolism and apoptosis-related genes results in significant synergy in the inhibition of cell growth and induction of apoptosis. Given the fact that ribitol is a metabolite with limited side effects, a combined therapy is highly desirable with relative ease to apply in the clinic for treating an appropriate cancer population. Our results also emphasize that, similar to traditional drug development, the therapeutic potential of targeting metabolism for cancer treatment may only be achieved in combination with other drugs and requires the identification of a specific cancer population. The desire to apply metabolomic intervention to a large scope of cancer types may be one of the reasons identification of this class of drugs in a clinical trial setting has been delayed.<\/jats:p>","DOI":"10.3390\/cancers15174356","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T08:45:31Z","timestamp":1693557931000},"page":"4356","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer"],"prefix":"10.3390","volume":"15","author":[{"given":"Ravi","family":"Doddapaneni","sequence":"first","affiliation":[{"name":"McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Wake Forest University School of Medicine, 1000 Blythe Blvd., Charlotte, NC 28231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6558-7808","authenticated-orcid":false,"given":"Jason D.","family":"Tucker","sequence":"additional","affiliation":[{"name":"McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Wake Forest University School of Medicine, 1000 Blythe Blvd., Charlotte, NC 28231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei J.","family":"Lu","sequence":"additional","affiliation":[{"name":"McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Wake Forest University School of Medicine, 1000 Blythe Blvd., Charlotte, NC 28231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi L.","family":"Lu","sequence":"additional","affiliation":[{"name":"McColl-Lockwood Laboratory for Muscular Dystrophy Research, Atrium Health Musculoskeletal Institute, Wake Forest University School of Medicine, 1000 Blythe Blvd., Charlotte, NC 28231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Konat-B\u0105ska, K., Matkowski, R., B\u0142aszczyk, J., B\u0142aszczyk, D., Staszek-Szewczyk, U., Pi\u0142at-Norkowska, N., and Maciejczyk, A. (2020). Does Breast Cancer Increasingly Affect Younger Women?. Int. J. Environ. Res. Public Health, 17.","DOI":"10.3390\/ijerph17134884"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1038\/s41467-018-05990-z","article-title":"Ribitol restores functionally glycosylated \u03b1-dystroglycan and improves muscle functions in dystrophic FKRP-mutant mice","volume":"9","author":"Cataldi","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1038\/s41598-020-61747-z","article-title":"Ribitol enhances matriglycan of \u03b1-dystroglycan in breast cancer cells without affecting cell growth","volume":"10","author":"Lu","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4161\/cbt.6.12.4983","article-title":"Expression of dystroglycan correlates with tumor grade and predicts survival in renal cell carcinoma","volume":"6","author":"Sgambato","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4161\/cbt.3.10.1132","article-title":"Increased expression of dystroglycan inhibits the growth and tumorigenicity of human mammary epithelial cells","volume":"3","author":"Sgambato","year":"2004","journal-title":"Cancer Biol. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11279","DOI":"10.1074\/jbc.C900007200","article-title":"Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE","volume":"284","author":"Inamori","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e0278711","DOI":"10.1371\/journal.pone.0278711","article-title":"Ribitol alters multiple metabolic pathways of central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics profiling of breast cancer","volume":"17","author":"Tucker","year":"2022","journal-title":"PLoS ONE"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.bbcan.2017.08.004","article-title":"Approaches and techniques to characterize cancer metabolism in vitro and in vivo","volume":"1868","author":"Zaimenko","year":"2017","journal-title":"Biochim. Et Biophys. Acta Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1021\/bp070301d","article-title":"Metabolic and morphological differences between rapidly proliferating cancerous and normal breast epithelial cells","volume":"24","author":"Meadows","year":"2008","journal-title":"Biotechnol. Prog."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e61578","DOI":"10.1371\/journal.pone.0061578","article-title":"Feasibility of MR metabolomics for immediate analysis of resection margins during breast cancer surgery","volume":"8","author":"Bathen","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0254-6272(14)60073-X","article-title":"An magnetic resonance-based plasma metabonomic investigation on abnormal Savda in different complicated diseases","volume":"34","author":"Mamtimin","year":"2014","journal-title":"J. Tradit. Chin. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ab.2015.07.015","article-title":"Characterization of metabolic profile of intact non-tumor and tumor breast cells by high-resolution magic angle spinning nuclear magnetic resonance spectroscopy","volume":"488","author":"Maria","year":"2015","journal-title":"Anal. Biochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3389\/fonc.2020.00317","article-title":"Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment","volume":"10","author":"Lin","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e0190958","DOI":"10.1371\/journal.pone.0190958","article-title":"Multiplatform plasma metabolic and lipid fingerprinting of breast cancer: A pilot control-case study in Colombian Hispanic women","volume":"13","author":"Cala","year":"2018","journal-title":"PLoS ONE"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jpba.2018.07.024","article-title":"Metabolic fingerprinting in breast cancer stages through (1)H NMR spectroscopy-based metabolomic analysis of plasma","volume":"160","author":"Suman","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s10549-019-05330-9","article-title":"Salivary metabolomics with alternative decision tree-based machine learning methods for breast cancer discrimination","volume":"177","author":"Murata","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrc.2016.77","article-title":"Reprogramming glucose metabolism in cancer: Can it be exploited for cancer therapy?","volume":"16","author":"Hay","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1073\/pnas.94.13.6658","article-title":"c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth","volume":"94","author":"Shim","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","article-title":"Understanding the Intersections between Metabolism and Cancer Biology","volume":"168","author":"DeBerardinis","year":"2017","journal-title":"Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"537930","DOI":"10.3389\/fonc.2020.537930","article-title":"Metabolic Targeting of Cancer Stem Cells","volume":"10","author":"Mukha","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/nrc1478","article-title":"Why do cancers have high aerobic glycolysis?","volume":"4","author":"Gatenby","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/2040620715576662","article-title":"Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: Emerging preclinical and clinical evidence","volume":"6","author":"Chaidos","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.breast.2020.08.005","article-title":"The emerging role of BET inhibitors in breast cancer","volume":"53","author":"Andrikopoulou","year":"2020","journal-title":"Breast"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7139","DOI":"10.1158\/1078-0432.CCR-19-0713","article-title":"BET inhibition as a rational therapeutic strategy for invasive lobular breast cancer","volume":"25","author":"Walsh","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ccell.2015.09.005","article-title":"An epigenetic pathway regulates sensitivity of breast cancer cells to HER2 inhibition via FOXO\/c-Myc Axis","volume":"28","author":"Matkar","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cell.2015.11.062","article-title":"Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance","volume":"164","author":"Marcotte","year":"2016","journal-title":"Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eaal1645","DOI":"10.1126\/scitranslmed.aal1645","article-title":"Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition","volume":"9","author":"Yang","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"51621","DOI":"10.18632\/oncotarget.18255","article-title":"Bromodomain inhibition shows antitumoral activity in mice and human luminal breast cancer","volume":"8","author":"Roa","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","unstructured":"(2022, November 05). A Dose-Finding Study of MK-8628. Adults with Selected Advanced Solid Tumors (MK-8628-003)\u2014Full Text View\u2014ClinicalTrials.gov n.d. A Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02259114."},{"key":"ref_32","unstructured":"(2023, January 16). A Two Part Study of RO6870810. Dose-Escalation Study in Participants with Advanced Solid Tumors and Expansion Study in Participants with Selected Malignancies\u2014Full Text View\u2014ClinicalTrials.gov n.d, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01987362."},{"key":"ref_33","unstructured":"(2023, January 16). Open-Label Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies\u2014Full Text View\u2014ClinicalTrials.gov n.d, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02711137."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","article-title":"Development of 2 bromodomain and extraterminal inhibitors with distinct pharmacokinetic and pharmacodynamic profiles for the treatment of advanced malignancies a C","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_35","unstructured":"(2023, April 12). An Open-Label Dose-Escalation Study of INCB054329 in Patients with Advanced Malignancies\u2014Full Text View\u2014ClinicalTrials.gov n.d, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02431260."},{"key":"ref_36","unstructured":"(2023, May 01). Study of BMS-986158 in Subjects with Select Advanced Cancers\u2014Full Text View\u2014ClinicalTrials.gov n.d, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02419417."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.18632\/oncotarget.2964","article-title":"Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers","volume":"6","author":"Bihani","year":"2015","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/cr.2014.71","article-title":"An epigenomic approach to therapy for tamoxifen-resistant breast cancer","volume":"24","author":"Feng","year":"2014","journal-title":"Cell Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"33623","DOI":"10.18632\/oncotarget.5601","article-title":"Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells","volume":"6","author":"Borbely","year":"2015","journal-title":"Oncotarget"},{"key":"ref_40","first-page":"1021","article-title":"General mechanism of JQ1 in inhibiting various types of cancer","volume":"21","author":"Jiang","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1002\/jcb.25863","article-title":"The BET Bromodomain Inhibitor JQ1 Suppresses Chondrosarcoma Cell Growth via Regulation of YAP\/p21\/c-Myc Signaling","volume":"118","author":"Zhang","year":"2017","journal-title":"J. Cell Biochem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"6915","DOI":"10.18632\/oncotarget.3126","article-title":"JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer","volume":"6","author":"Qiu","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e923411","DOI":"10.12659\/MSM.923411","article-title":"Bromodomains and Extra-Terminal (BET) Inhibitor JQ1 Suppresses Proliferation of Acute Lymphocytic Leukemia by Inhibiting c-Myc-Mediated Glycolysis","volume":"26","author":"Zhang","year":"2020","journal-title":"Med. Sci. Monit."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat. Rev. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4356\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:44:29Z","timestamp":1760129069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/17\/4356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":44,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["cancers15174356"],"URL":"https:\/\/doi.org\/10.3390\/cancers15174356","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}